Literature DB >> 33376402

Predicting Prostate Cancer Upgrading of Biopsy Gleason Grade Group at Radical Prostatectomy Using Machine Learning-Assisted Decision-Support Models.

Hailang Liu1, Kun Tang1, Ejun Peng1, Liang Wang2, Ding Xia1, Zhiqiang Chen1.   

Abstract

OBJECTIVE: This study aimed to develop a machine learning (ML)-assisted model capable of accurately predicting the probability of biopsy Gleason grade group upgrading before making treatment decisions.
METHODS: We retrospectively collected data from prostate cancer (PCa) patients. Four ML-assisted models were developed from 16 clinical features using logistic regression (LR), logistic regression optimized by least absolute shrinkage and selection operator (Lasso) regularization (Lasso-LR), random forest (RF), and support vector machine (SVM). The area under the curve (AUC) was applied to determine the model with the highest discrimination. Calibration plots and decision curve analysis (DCA) were performed to evaluate the calibration and clinical usefulness of each model.
RESULTS: A total of 530 PCa patients were included in this study. The Lasso-LR model showed good discrimination with an AUC, accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 0.776, 0.712, 0.679, 0.745, 0.730, and 0.695, respectively, followed by SVM (AUC=0.740, 95% confidence interval [CI]=0.690-0.790), LR (AUC=0.725, 95% CI=0.674-0.776) and RF (AUC=0.666, 95% CI=0.618-0.714). Validation of the model showed that the Lasso-LR model had the best discriminative power (AUC=0.735, 95% CI=0.656-0.813), followed by SVM (AUC=0.723, 95% CI=0.644-0.802), LR (AUC=0.697, 95% CI=0.615-0.778) and RF (AUC=0.607, 95% CI=0.531-0.684) in the testing dataset. Both the Lasso-LR and SVM models were well-calibrated. DCA plots demonstrated that the predictive models except RF were clinically useful.
CONCLUSION: The Lasso-LR model had good discrimination in the prediction of patients at high risk of harboring incorrect Gleason grade group assignment, and the use of this model may be greatly beneficial to urologists in treatment planning, patient selection, and the decision-making process for PCa patients.
© 2020 Liu et al.

Entities:  

Keywords:  Gleason grade group; biopsy cores; machine learning; prostate cancer; upgrading

Year:  2020        PMID: 33376402      PMCID: PMC7765752          DOI: 10.2147/CMAR.S286167

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


  35 in total

1.  Gleason score correlation between biopsy and prostatectomy specimens and prediction of high-grade Gleason patterns: significance of central pathologic review.

Authors:  Kentaro Kuroiwa; Taizo Shiraishi; Seiji Naito
Journal:  Urology       Date:  2010-08-21       Impact factor: 2.649

Review 2.  Machine Learning in Medicine.

Authors:  Alvin Rajkomar; Jeffrey Dean; Isaac Kohane
Journal:  N Engl J Med       Date:  2019-04-04       Impact factor: 91.245

3.  Global Gleason grade groups in prostate cancer: concordance of biopsy and radical prostatectomy grades and predictors of upgrade and downgrade.

Authors:  Daniel Athanazio; Geoffrey Gotto; Melissa Shea-Budgell; Asli Yilmaz; Kiril Trpkov
Journal:  Histopathology       Date:  2017-03-28       Impact factor: 5.087

4.  Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.

Authors:  Pietro Pepe; Antonio Garufi; Gian Domenico Priolo; Antonio Galia; Filippo Fraggetta; Michele Pennisi
Journal:  J Urol       Date:  2018-04-19       Impact factor: 7.450

5.  Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.

Authors:  Christian Thomas; Karin Pfirrmann; Frauke Pieles; Alexander Bogumil; Rolf Gillitzer; Christoph Wiesner; Joachim W Thüroff; Sebastian W Melchior
Journal:  BJU Int       Date:  2011-05-18       Impact factor: 5.588

6.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

7.  The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.

Authors:  Giorgio Gandaglia; Guillaume Ploussard; Massimo Valerio; Agostino Mattei; Cristian Fiori; Mathieu Roumiguié; Nicola Fossati; Armando Stabile; Jean-Baptiste Beauval; Bernard Malavaud; Simone Scuderi; Francesco Barletta; Marco Moschini; Stefania Zamboni; Arnas Rakauskas; Zhe Tian; Pierre I Karakiewicz; Francesco De Cobelli; Francesco Porpiglia; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2019-09-21       Impact factor: 20.096

8.  A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.

Authors:  Giorgio Gandaglia; Guillaume Ploussard; Massimo Valerio; Agostino Mattei; Cristian Fiori; Nicola Fossati; Armando Stabile; Jean-Baptiste Beauval; Bernard Malavaud; Mathieu Roumiguié; Daniele Robesti; Paolo Dell'Oglio; Marco Moschini; Stefania Zamboni; Arnas Rakauskas; Francesco De Cobelli; Francesco Porpiglia; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2018-10-17       Impact factor: 20.096

9.  Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.

Authors:  Matteo Ferro; Giuseppe Lucarelli; Dario Bruzzese; Giuseppe Di Lorenzo; Sisto Perdonà; Riccardo Autorino; Francesco Cantiello; Roberto La Rocca; Gian Maria Busetto; Amelia Cimmino; Carlo Buonerba; Michele Battaglia; Rocco Damiano; Ottavio De Cobelli; Vincenzo Mirone; Daniela Terracciano
Journal:  Oncotarget       Date:  2017-03-14

10.  Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates.

Authors:  Muammer Altok; Patricia Troncoso; Mary F Achim; Surena F Matin; Graciela N Gonzalez; John W Davis
Journal:  Asian J Androl       Date:  2019 Nov-Dec       Impact factor: 3.285

View more
  2 in total

1.  Discriminatory Gleason grade group signatures of prostate cancer: An application of machine learning methods.

Authors:  Mpho Mokoatle; Darlington Mapiye; Vukosi Marivate; Vanessa M Hayes; Riana Bornman
Journal:  PLoS One       Date:  2022-06-09       Impact factor: 3.752

2.  Machine Learning-Based Prediction of Pathological Upgrade From Combined Transperineal Systematic and MRI-Targeted Prostate Biopsy to Final Pathology: A Multicenter Retrospective Study.

Authors:  Junlong Zhuang; Yansheng Kan; Yuwen Wang; Alessandro Marquis; Xuefeng Qiu; Marco Oderda; Haifeng Huang; Marco Gatti; Fan Zhang; Paolo Gontero; Linfeng Xu; Giorgio Calleris; Yao Fu; Bing Zhang; Giancarlo Marra; Hongqian Guo
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.